OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
October 14, 2021
Enzyvant’s Rethymic is the first FDA approved treatment for congenital athymia.
Element’s acquisition of Nanosyn is the latest in a series of moves made to strengthen the company’s North American presence.
MHRA has awarded an ‘Innovation Passport’ to CellResearch for its umbilical cord lining stem cell therapy, CorLiCyte.
October 13, 2021
Pacira’s acquisition grants them access to Flexion’s pain management portfolio.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.
October 08, 2021
The approval of ChemoCentryx’s Tavenos (avacopan) provides a new treatment for active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
AstraZeneca’s tezelpelumab was granted orphan drug designation by FDA for the treatment of eosinophilic esophagitis.
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.